

S2 Table. Clinical characteristics between the RR-CHOP group and the historical R-CHOP group

	RR-CHOP (n=72)	R-CHOP (n=72)	p-value
Age \geq 60 yr	45 (62.5)	43 (59.7)	0.864
Sex			
Male/Female	43/29 (63.0/37.0)	44/28 (61.1/38.9)	0.999
Ann Arbor stage			0.120
II/ III-IV	4/68 (5.6/94.4)	0/72 (0/100.0)	
Bulky disease (\geq 10 cm)	14 (19.4)	7 (9.7)	0.755
B symptom	15 (20.8)	21 (29.2)	0.336
Elevated serum lactate dehydrogenase	51 (70.8)	53 (73.6)	0.853
ECOG performance status			
0 or 1/ \geq 2	61/ 11 (84.7/15.3)	58/14 (80.6/19.4)	0.661
Extranodal involvement			
0 or 1/ \geq 2	26/46 (36.1/63.9)	21/51 (29.2/70.8)	0.477
Bone marrow involvement	11/72 (15.3)	13/70 (18.6)	0.658
International Prognostic Index			0.686
Low-risk/Low-intermediate risk	3/13 (4.2/18.1)	5/11 (6.9/15.3)	
High-intermediate risk/High-risk	36/20 (50.0/27.8)	31/25 (43.1/34.7)	
Revised International Prognostic Index			0.999
Good/ Poor	16/ 56 (22.2/77.8)	15/ 57 (20.8/79.2)	
Cell of origin			0.208
Germinal center B-cell type	20/52 (38.5)	13/50 (26.0)	
Non-Germinal center B-cell type	32/62 (61.5)	37/50 (74.0)	
Bcl-2 positive	43/60 (71.7)	38/60 (63.3)	0.436
Bcl-6 positive	38/53 (71.7)	34/61 (55.7)	0.084

Values are presented as number (%). ECOG, Eastern Cooperative Oncology Group; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; RR-CHOP, intensified the first cycle of rituximab plus eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab.